Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | CTSC | P53634 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 3/20 | 0.49 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12104067 | 1.00 | SLC6A2 (0.59) | SLC6A2SLC6A3SLC6A4CTSCDPP4 | |
| SCHEMBL12188513 | 1.00 | SLC6A2 (0.59) | SLC6A2SLC6A3SLC6A4CTSCDPP4 | |
| SCHEMBL5096121 | 0.84 | SLC6A4 (0.57) | SLC6A2SLC6A3SLC6A4CTSCDPP4 | |
| Fenclonine SCHEMBL3140768 | 0.84 | SLC7A5 (0.69) | SLC6A2SLC6A3SLC6A4SLC7A5ALPI | |
| Fenclonine SCHEMBL26382 | 0.84 | SLC7A5 (0.69) | SLC6A2SLC6A3SLC6A4SLC7A5ALPI | |
| Fenclonine SCHEMBL245828 | 0.84 | SLC7A5 (0.69) | SLC6A2SLC6A3SLC6A4SLC7A5ALPI | |
| SCHEMBL8122168 | 0.84 | SLC6A4 (0.57) | SLC6A2SLC6A3SLC6A4CTSCDPP4 | |
| Fenclonine SCHEMBL26383 | 0.84 | SLC7A5 (0.69) | SLC6A2SLC6A3SLC6A4SLC7A5ALPI | |
| SCHEMBL6317469 | 0.84 | SLC6A4 (0.57) | SLC6A2SLC6A3SLC6A4CTSCDPP4 | |
| SCHEMBL3773871 | 0.83 | SLC6A2 (0.52) | SLC6A2SLC6A3SLC6A4ACACBPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000808-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2017-01-05 | — | — | US | disclosed |
| US-9440995-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-09-13 | — | — | US | disclosed |
| US-9233985-B2 | Arginase inhibitors as therapeutics | MARS, INCORPORATED (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2015-07-09 | — | — | US | disclosed |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | MARS, INCORPORATED | 2012-05-24 | — | — | US | disclosed |
| EP-1996588-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | Torrent Pharmaceuticals Ltd (IN) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007100295-A1 | NOVEL DUAL ACTION RECEPTORS ANTAGONISTS (DARA) AT THE ATI AND ETA RECEPTORS | TORRENT PHARMACEUTICALS LTD (IN) | 2007-09-07 | — | — | WO | disclosed |
| US-7186715-B2 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| WO-2001009125-A1 | NOVEL 8-CARBONYL CHROMAN DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000808-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | SLC6A2 3513/4885SLC6A3 4039/4885SLC6A4 4455/4885 |
| US-20120129806-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | SLC6A2 3513/4885SLC6A3 4039/4885SLC6A4 4455/4885 |
| US-20150191492-A1 | ARGINASE INHIBITORS AS THERAPEUTICS | ARG1, ARG2, PRMT1 | SLC6A2 3513/4885SLC6A3 4039/4885SLC6A4 4455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.